mitoxantrone has been researched along with Jejunal Diseases in 1 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Jejunal Diseases: Pathological development in the JEJUNUM region of the SMALL INTESTINE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 44-year-old man who had achieved a complete remission of malignant peritoneal mesothelioma after the intraperitoneal administration of 25 mg/m2 mitoxantrone presented with clinical and radiological signs of intestinal obstruction suggestive of recurrent disease at about 2 years following the initial treatment." | 7.68 | Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. ( Gallee, MP; Kroon, BB; Rodenhuis, S; Taal, BG; Vlasveld, LT, 1992) |
| "A 44-year-old man who had achieved a complete remission of malignant peritoneal mesothelioma after the intraperitoneal administration of 25 mg/m2 mitoxantrone presented with clinical and radiological signs of intestinal obstruction suggestive of recurrent disease at about 2 years following the initial treatment." | 3.68 | Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. ( Gallee, MP; Kroon, BB; Rodenhuis, S; Taal, BG; Vlasveld, LT, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vlasveld, LT | 1 |
| Taal, BG | 1 |
| Kroon, BB | 1 |
| Gallee, MP | 1 |
| Rodenhuis, S | 1 |
1 other study available for mitoxantrone and Jejunal Diseases
| Article | Year |
|---|---|
Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone.
Topics: Adult; Biopsy; Fibrosis; Humans; Injections, Intraperitoneal; Intestinal Obstruction; Jejunal Diseas | 1992 |